Herwig R, Mitteregger D, Djavan B, Kramer G, Margreiter M, Leers M P, Glodny B, Haider D G, Hörl W H, Marberger M
Department of Urology, Medical University Vienna, Vienna, Austria.
Eur J Clin Invest. 2008 Jun;38(6):430-7. doi: 10.1111/j.1365-2362.2008.01953.x.
Serum prostate-specific antigen (PSA) is a standard method and a widely used marker for prostate cancer, but it has a poor specificity for early detection. Herein we demonstrate that intracellular macrophage PSA (imPSA) enables screening and differentiation between benign and malignant prostate disease.
The efficacy of intracellular macrophage PSA in circulating and tissue macrophages was therefore investigated in a double-centre study of 38 prostate cancer patients and 36 healthy controls by fluorescent-activated cell sorting analysis and immunohistology.
Both methods uncovered the existence of PSA-positive macrophages specific for patients with prostate cancer. In addition, we demonstrate the superiority of our new test over standard serum total PSA in a blinded double-centre trial. ImPSA had a marked higher sensitivity and specificity than serum total PSA (imPSA: sensitivity 92%, specificity 92%, positive predictive value 92%; serum total PSA: sensitivity 79.5%, specificity 87.5%, positive predictive value 26.8%).
In this study, we demonstrate that imPSA is a new prostate cancer screening method that is highly sensitive and more specific than standard PSA testing.
血清前列腺特异性抗原（PSA）是前列腺癌的一种标准检测方法且被广泛应用，但它在早期检测方面特异性较差。在此我们证明，细胞内巨噬细胞PSA（imPSA）能够对良性和恶性前列腺疾病进行筛查与鉴别。
因此，在一项针对38例前列腺癌患者和36例健康对照者的双中心研究中，通过荧光激活细胞分选分析和免疫组织学方法，对循环及组织巨噬细胞中的细胞内巨噬细胞PSA的效能进行了研究。
两种方法均发现了前列腺癌患者特有的PSA阳性巨噬细胞的存在。此外，在一项双盲双中心试验中，我们证明了我们的新检测方法优于标准血清总PSA检测。ImPSA的敏感性和特异性显著高于血清总PSA（imPSA：敏感性92%，特异性92%，阳性预测值92%；血清总PSA：敏感性79.5%，特异性87.5%，阳性预测值26.8%）。
在本研究中，我们证明imPSA是一种新的前列腺癌筛查方法，它比标准PSA检测具有更高的敏感性和特异性。
